芯碁微裝(688630.SH):擬在境外發行股份(H股)並在香港聯交所上市
格隆匯6月27日丨芯碁微裝(688630.SH)公佈,為加快公司的國際化戰略及海外業務佈局,打造國際化資本運作平台,進一步提升公司品牌形象及知名度,提高公司的資本實力和綜合競爭力,根據公司總體發展戰略及運營需要,公司擬在境外發行股份(H股)並在香港聯合交易所有限公司(簡稱“香港聯交所”)上市。公司董事會同意授權公司管理層啟動本次H股上市的前期籌備工作,授權期限為自董事會審議通過之日起12個月內。公司計劃與相關中介機構就本次H股上市的具體推進工作進行商討,關於本次H股上市的具體細節尚未最終確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.